Publications
5808 Results
- Journal / Conference
- Int J Epidemiol, 52(1), 71-86
- Year
- 2023
- Research Committee(s)
- Prevention, Screening, and and Surveillance
Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis
- Journal / Conference
- Qual Life Res. 2023 May;32(5):1231-1238
- Year
- 2023
- Research Committee(s)
- Symptom Management and Survivorship
Common Methods of Determining Meaningful Change in Clinical Practice: Implications for Precision Patient-Reported Outcomes
- Journal / Conference
- Nutrition and Cancer 74(1):141-148
- Year
- 2022
- Research Committee(s)
- Cancer Control
- PMID
- PMID33511883
- PMC
- PMC8319215
- Study Number(s)
- SWOG-9217
Association of Serum Carotenoids and Retinoids with Intraprostatic Inflammation in Men without Prostate Cancer or Clinical Indication for Biopsy in the Placebo Arm of the Prostate Cancer Prevention Trial
- Journal / Conference
- International Journal of Cancer, Jan 15;150(2):279-289. doi: 10.1002/ijc.33810. Epub 2021 Oct 5
- Year
- 2022
- Research Committee(s)
- Breast and Gastrointestinal
- PMID
- PMID34528705
- Study Number(s)
- CTSU/C40503, CTSU/C80405
Genome-wide association studies of survival in 1,520 cancer patients treated with bevacizumab-containing regimens
- Journal / Conference
- Clinical Cancer Research, Jan 15;28(2):271-278
- Year
- 2022
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID34716198
- PMC
- PMC8776596
- Study Number(s)
- S1609
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609)
- Journal / Conference
- Clinical Lung Cancer Jan;23(1):60-71
- Year
- 2022
- Research Committee(s)
- Lung
- PMID
- PMID34753703
- PMC
- PMC8766941
- Study Number(s)
- S0819
EGFR High Copy Number Together with High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis from SWOG S0819, a phase III trial of chemotherapy with or without Cetuximab in advanced NSCLC
- Journal / Conference
- Oncogene Jan;41(2):260-267
- Year
- 2022
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID34728807
- PMC
- PMC8738154
- Study Number(s)
- CTSU/C80405
Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer
- Journal / Conference
- Journal of Geriatric Oncology, Mar;13(2):258-264
- Year
- 2022
- Research Committee(s)
- Lymphoma
- PMID
- PMID34686472
- PMC
- PMC9879719
- Study Number(s)
- S1918
SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas – Aiming to improve therapy, outcomes, and validate a prospective frailty tool
- Journal / Conference
- Clinical Cancer Research Feb 15;28(4):611-617
- Year
- 2022
- Research Committee(s)
- Breast
- PMID
- PMID34844978
- PMC
- PMC9782801
- Study Number(s)
- S1222
A randomized trial of fulvestrant, everolimus and anastrozole in the front line treatment of advanced hormone receptor positive breast cancer, SWOG S1222
- Journal / Conference
- Endocrine-Related Cancer Jan 20;29(2):99-109. doi: 10.1530/ERC-21-0107
- Year
- 2022
- Research Committee(s)
- Cancer Control
- PMID
- PMID34889205
- PMC
- PMC8776589
- Study Number(s)
- SWOG-9217